Nisa Investment Advisors LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 76.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 433 shares of the biopharmaceutical company’s stock after selling 1,396 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Ultragenyx Pharmaceutical were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in RARE. Alpha Paradigm Partners LLC purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $113,000. Harbor Capital Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth about $169,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth about $207,000. Alta Wealth Advisors LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth about $218,000. Finally, Advisor Group Holdings Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 75.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,830 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 1,218 shares during the period. 97.49% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
RARE has been the topic of a number of research reports. StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, June 21st. The Goldman Sachs Group lowered their target price on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating for the company in a research note on Tuesday, May 24th. Barclays lowered their target price on Ultragenyx Pharmaceutical from $141.00 to $105.00 in a research note on Friday. Cowen lowered their target price on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a research note on Friday, May 6th. Finally, Stifel Nicolaus lowered their target price on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating for the company in a research note on Friday, July 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Hold” and a consensus price target of $108.42.
Ultragenyx Pharmaceutical Trading Up 2.7 %
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.54). The firm had revenue of $89.34 million during the quarter, compared to analyst estimates of $87.33 million. Ultragenyx Pharmaceutical had a negative return on equity of 49.18% and a negative net margin of 141.65%. Ultragenyx Pharmaceutical’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.45) EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.21 earnings per share for the current fiscal year.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.